FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer By Ogkologos - May 13, 2026 120 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR Cancer in children and young people: how far we’ve come September 29, 2021 ASCO Annual Meeting 2023: Trastuzumab Deruxtecan Effectively Treats HER2-Expressing Tumors and... June 5, 2023 Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 7 ways we’ve influenced progress in lung cancer November 1, 2022 Load more HOT NEWS A Personalised Prediction Model Based on Clinical and Genomic Data Outperforms... A Third Dose of BNT162b2 is Safe and Improves Humoural Immunity... FDA Approves Second CAR T-Cell Therapy for Lymphoma Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab
